Ph. Rougier, J. Oliveira, M. Ducreux, C. Theodore, J. Kac, J.P. Droz
{"title":"胰腺转移性类癌和胰岛细胞肿瘤:5-氟尿嘧啶、阿霉素和顺铂联合化疗疗效的II期试验","authors":"Ph. Rougier, J. Oliveira, M. Ducreux, C. Theodore, J. Kac, J.P. Droz","doi":"10.1016/0277-5379(91)90014-5","DOIUrl":null,"url":null,"abstract":"<div><p>A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m<sup>2</sup> per day (5-FU) for 3 days, 50 mg/m<sup>2</sup> doxorubicin on day 2, and 90 mg/m<sup>2</sup> cisplatin on day 2, repeated every 4 weeks. 24 patients, 20 non-pretreated and 4 pretreated, were included. For non-pretreated patients we observed 1 complete response and 2 partial responses. The response rate was 15% (95% confidence interval 0–31%). No response was observed in the pretreated patients. The toxicity was mainly digestive and haematological with 7 patients experiencing vomiting grade 3 and 3 patients with leucopenia grade 3. We conclude that the FAP protocol is of poor efficiency in endocrine tumours.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 11","pages":"Pages 1380-1382"},"PeriodicalIF":0.0000,"publicationDate":"1991-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90014-5","citationCount":"48","resultStr":"{\"title\":\"Metastatic carcinoid and islet cell tumours of the pancreas: A phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin\",\"authors\":\"Ph. Rougier, J. Oliveira, M. Ducreux, C. Theodore, J. Kac, J.P. Droz\",\"doi\":\"10.1016/0277-5379(91)90014-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m<sup>2</sup> per day (5-FU) for 3 days, 50 mg/m<sup>2</sup> doxorubicin on day 2, and 90 mg/m<sup>2</sup> cisplatin on day 2, repeated every 4 weeks. 24 patients, 20 non-pretreated and 4 pretreated, were included. For non-pretreated patients we observed 1 complete response and 2 partial responses. The response rate was 15% (95% confidence interval 0–31%). No response was observed in the pretreated patients. The toxicity was mainly digestive and haematological with 7 patients experiencing vomiting grade 3 and 3 patients with leucopenia grade 3. We conclude that the FAP protocol is of poor efficiency in endocrine tumours.</p></div>\",\"PeriodicalId\":11925,\"journal\":{\"name\":\"European Journal of Cancer and Clinical Oncology\",\"volume\":\"27 11\",\"pages\":\"Pages 1380-1382\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0277-5379(91)90014-5\",\"citationCount\":\"48\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0277537991900145\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0277537991900145","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Metastatic carcinoid and islet cell tumours of the pancreas: A phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin
A phase II trial of chemotherapy in carcinoid and islet cell pancreatic tumours has been conducted with the FAP protocol: 5-fluorouracil 400 mg/m2 per day (5-FU) for 3 days, 50 mg/m2 doxorubicin on day 2, and 90 mg/m2 cisplatin on day 2, repeated every 4 weeks. 24 patients, 20 non-pretreated and 4 pretreated, were included. For non-pretreated patients we observed 1 complete response and 2 partial responses. The response rate was 15% (95% confidence interval 0–31%). No response was observed in the pretreated patients. The toxicity was mainly digestive and haematological with 7 patients experiencing vomiting grade 3 and 3 patients with leucopenia grade 3. We conclude that the FAP protocol is of poor efficiency in endocrine tumours.